Skip to main content
. 2024 Nov 20;16(22):3885. doi: 10.3390/cancers16223885

Table 2.

Ongoing clinical trials of combination therapies with KRAS inhibitors.

Combination Strategy Compound Clinical Trial Indication
Combination with Chemo, RT and/or ICI Adagrasib
  • -

    Adagrasib in combination with Nivolumab in the neoadjuvant setting (NCT05472623)

  • -

    Adagrasib in combination with stereotactic radiosurgery in metastatic NSCLC (NCT06248606)

  • -

    Adagrasib in combination therapy in advanced NSCLC (NCT05609578)

  • -

    Adagrasib in combination with small molecule PD-L1 inhibitor INCB099280 in advanced solid tumors
Olomorasib
(LY3537982)
  • -

    In combination with Pembrolizumab in first line (NCT04613596)

  • -

    In combination with the standard of care in untreated advanced NSCLC (NCT06119581)
Sotorasib
  • -

    Platinum doublet combination versus Pembrolizumab platinum doublet combination as frontline therapy in IV or stage IIIB/C nonsquamous NSCLC (NCT05920356)

  • -

    With stereotactic radiation therapy in patients with advanced NSCLC who have received at least one line of standard medical management (NCT06127940)
BBO-8520
  • -

    In combination with Pembrolizumab in advanced NSCLC (NCT06343402)
MK-1084
  • -

    With pembrolizumab as first-line treatment in metastatic NSCLC in TPS ≥ 50% (NCT06345729)
Fulzerasib(IBI351)
  • -

    In combination with Sintilimab ± chemotherapy in advanced non-squamous NSCLC (NCT05504278)
Garsorasib
(D-1553)-
  • -

    In combination therapy in locally advanced or metastatic NSCLC (NCT05492045)
GFH925
  • -

    In combination with Cetuximab in advanced NSCLC (NCT05756153)
Divarasib
(GDC-6036)
  • -

    Combined with chemotherapy or ICI in previously untreated, advanced or metastatic NSCLC (NCT05789082)
RMC-6291 or RMC-6236
  • -

    Combined with standard of care in KRAS G12C- or pan-RAS-mutated advanced solid tumors (NCT06162221)
Combination with SHP2/SOS1 Sotorasib
  • -

    In combination with SHP2 inhibitor BBP-398 in locally advanced or metastatic subjects after the failure of prior standard therapies (NCT05480865)

  • -

    In combination with RMC-4630 after the failure of standard treatment (NCT05054725)
Adagrasib
  • -

    In combination with TNO155 in advanced solid tumors (NCT04330664)
Glecirasib and JAB 3312
Other combinations Sotorasib with Ras-Raf-Mek-ERK inhibitor
  • -

    In combination with Avutometinib and/or Defactinib in stage IIIB-IV (NCT05074810)
Sotorasib with proteosome inhibitor
  • -

    In combination with Carfilzomib in advanced or metastatic NSCLC (NCT06249282)
Sotorasib in combination with IL-8 receptor inhibitor
  • -

    In combination with Ladarixin in advanced NSCLC (NCT05815173)
Adagrasib with pan-KRAS inhibitor
  • -

    In combination with BI 1701963 for metastatic disease (NCT04975256)
Adagrasib with mTOR inhibitor
  • -

    In combination with Nab-Sirolimus in advanced solid tumors (NCT05840510)
Adagrasib with PARP inhibitor
  • -

    In combination with Olaparib in advanced solid tumors (NCT06130254)
Adagrasib with RAF/MEK clamp
  • -

    In combination with VS-6766 in second line NSCLC (NCT05375994)
KRAS:KRAS G12C ON inhibitor
  • -

    RMC-6291 in combination with RMC-6236 in advanced solid tumors (NCT06128551)